MAIA Biotechnology (NYSEAMERICAN:MAIA) CEO Vlad Vitoc Acquires 73,000 Shares of Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) CEO Vlad Vitoc bought 73,000 shares of the stock in a transaction dated Monday, September 14th. The stock was purchased at an average cost of $1.37 per share, with a total value of $100,010.00. Following the completion of the purchase, the chief executive officer directly owned 1,049,121 shares in the company, valued at approximately $1,437,295.77. This trade represents a 7.48% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

MAIA Biotechnology Stock Down 3.6%

MAIA stock opened at $1.34 on Wednesday. The company has a market cap of $81.51 million, a P/E ratio of -2.16 and a beta of 0.25. MAIA Biotechnology, Inc. has a twelve month low of $0.87 and a twelve month high of $3.19. The business has a fifty day moving average of $1.35 and a 200-day moving average of $1.38.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, equities research analysts anticipate that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MAIA Biotechnology

Several institutional investors have recently modified their holdings of the business. Centric Wealth Management bought a new position in MAIA Biotechnology in the second quarter valued at approximately $1,107,000. Cable Car Capital LP acquired a new position in shares of MAIA Biotechnology in the 2nd quarter valued at $741,000. BlackRock Inc. acquired a new position in shares of MAIA Biotechnology in the 2nd quarter valued at $580,000. Corsair Capital Management L.P. bought a new position in shares of MAIA Biotechnology in the 1st quarter worth $140,000. Finally, Susquehanna International Group LLP bought a new position in shares of MAIA Biotechnology in the 2nd quarter worth $51,000. Institutional investors and hedge funds own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical?stage biopharmaceutical company developing a proprietary platform for site?specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody?based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high?contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody?radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.